Bloomberg News

Amarin Falls After Financing Suggests Buyout Not Imminent

December 07, 2012

Amarin Corp. (AMRN:US), the maker of the cholesterol-lowering medicine Vascepa, plunged the most in almost two years after investors lost confidence that the company will soon be acquired.

Amarin declined (AMRN:US) 19 percent to $9.69 at 4 p.m. New York time, the most since January 2010. The Dublin-based company’s shares have gained 31 percent in the past 12 months.

Investors had expected Amarin to sell itself or find a partner to market Vascepa, the company’s treatment for severely high levels of triglycerides, said Akiva Felt, an analyst for Wedbush Securities in San Francisco. Instead, the company announced yesterday that it raised $100 million and started hiring a sales force for the medicine. The financing from Pharmakon Advisors and the start of a sales force may mean no sale is on horizon, he said.

“The concern is that this may be a signal that a deal isn’t imminent,” Felt said in a telephone interview yesterday. “There had been expectations that there would be a strategic agreement in the near term.”

To contact the reporter on this story: Shannon Pettypiece in New York at spettypiece@bloomberg.net; Elizabeth Lopatto in New York at

elopatto@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Soul Searcher
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • AMRN
    (Amarin Corp PLC)
    • $1.59 USD
    • 0.06
    • 3.83%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus